Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVE-MORE: suPAR-guided early anakinra for COVID-19 respiratory failure prevention
2020-005828-11Phase 3Completed
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Dec 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and viral pneumonia comparing suPAR-guided anakinra with Placebo or standard of care (2 arms). Primary endpoint: Primary WHO Clinical Progression Scale state at Day 28. Started Dec 2020; status: completed.
02
Drugs
anakinra
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on 2020-005828-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005828-11.